Anne-Sophie Becker

Dr. Anne-Sophie Becker

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Oncotarget
Verified
Journal Article
Open access
PDF file
LALeonidas Apostolidis
Leonidas Apostolidis
CNCathleen Nientiedt
Cathleen Nientiedt
EWEva Caroline Winkler
Eva Caroline Winkler
ABAnne Katrin Berger
Anne Katrin Berger
CKClemens Kratochwil
Clemens Kratochwil
CGCarsten Grüllich
Carsten Grüllich
Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate

27 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ABAnne-Sophie Becker
Anne-Sophie Becker
CKCornelius Kluge
Cornelius Kluge
CSCarsten Schofeld
Carsten Schofeld
AZAnnette Helene Zimpfer
Annette Helene Zimpfer
BSBjoern Schneider
Bjoern Schneider
CMClaudia Maletzki
Claudia Maletzki
The 5-year survival rate for head and neck squamous cell carcinoma (HNSCC) is approximately 65%. In addition to radio-chemotherapy, immunotherapy is an approach in the treatment of advanced HNSCC. A better understanding of the immune context would allow personalized treatment by identifying patients who are best suited for different treatment options. In our discovery cohort, we evaluated the expression profiles of CMTM6, PD-L1, CTLA-4, and FOXP3 in 177 HNSCCs from Caucasian patients of all tumor stages and different treatment regimens, correlating marker expression in tumor and immune cells with outcomes. Patients with CMTM6high-expressing tumors had a longer overall survival regardless of treatment. This prognostic benefit of CMTM6 in HNSCC was validated in an independent cohort. Focusing on the in the discovery cohort (n = 177), a good predictive effect of CMTM6high expression was seen in patients receiving radiotherapy (p = 0.07; log rank), but not in others. CMTM6 correlated with PD-L1, CTLA-4 and FOXP3 positivity, with patients possessing CMTM6high/FOXP3high tumors showing the longest survival regardless of treatment. In chemotherapy-treated patients, PD-L1 positivity was associated with longer progression-free survival (p < 0.05). In the 27 patients who received immunotherapy, gene expression analysis revealed lower levels of CTLA-4 and FOXP3 with either partial or complete response to this treatment, while no effect was observed for CMTM6 or PD-L1. The combination of these immunomodulatory markers seems to be an interesting prognostic and predictive signature for HNSCC patients with the ability to optimize individualized treatments.

8 January 2024 in Oral Diseases
Verified
Journal Article
Open access
ABAnne-Sophie Becker
Anne-Sophie Becker
MHMaximiliane Holm
Maximiliane Holm
JLJan Liese
Jan Liese
Nadja EngelNadja Engel
Nadja Engel
AZAnnette Helene Zimpfer
Annette Helene Zimpfer
Objectives: The World Health Organization's definition of oral epithelial dysplasia includes differentiated dysplasia, which is defined by purely architectural abnormalities of oral mucosa without cytological changes. We analysed differentiated dysplasia's frequency, progression risk and correlation with oral brush cytology.Materials and Methods: Cytoarchitectural criteria and expression patterns of keratin 13/17 and ki67 were studied in oral biopsies clinically diagnosed with leukoplakia. Biopsies were assessed for dysplasia and its grade. Available brush cytology findings were obtained from clinical records.Results: We included 159 biopsies from 112 patients (33% differentiated dysplasia; 27% keratosis without dysplasia; oral epithelial dysplasia with atypia of mild, moderate and severe degree including invasive cancers in 9%, 8% and 7%, respectively). Keratin 13 loss and keratin 17 gain were higher in differentiated‐dysplasia cases (p < 0.0001), which had the highest hypergranulosis frequency. Keratin 17 expression was associated with higher malignant‐transformation rates (p = 0.0028). The transformation rate and time were comparable between dysplasia with atypia and differentiated‐dysplasia cases, which had higher progression rates and shorter time periods than keratosis cases without dysplasia (p = 0.08). Cytology prior to differentiated dysplasia all indicated normal oral mucosa.Conclusions: Keratin 17 but not oral brush cytology can help identify patients with differentiated dysplasia with higher risk for malignant transformation.

18 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
NSNina Schoenwaelder
Nina Schoenwaelder
MKMareike Krause
Mareike Krause
TFThomas Freitag
Thomas Freitag
BSBjoern Schneider
Bjoern Schneider
SZSarah Zonnur
Sarah Zonnur
CMClaudia Maletzki
Claudia Maletzki
This study aimed to refine combined targeted approaches on well-characterized, low-passage tumor models. Upon in vivo xenografting in immunodeficient mice, three cell lines from locally advanced or metastatic HNSCC were established. Following quality control and basic characterization, drug response was examined after therapy with 5-FU, Cisplatin, and cyclin-dependent kinase inhibitors (abemaciclib, THZ1). Our cell lines showed different in vitro growth kinetics, morphology, invasive potential, and radiosensitivity. All cell lines were sensitive to 5-FU, Cisplatin, and THZ1. One cell line (HNSCC48 P0 M1) was sensitive to abemaciclib. Here, Cyto-FISH revealed a partial CDKN2a deletion, which resulted from a R58* mutation. Moreover, this cell line demonstrated chromosome 12 polysomy, accompanied by an increase in CDK4-specific copy numbers. In HNSCC16 P1 M1, we likewise identified polysomy-associated CDK4-gains. Although not sensitive to abemaciclib per se, the cell line showed a G1-arrest, an increased number of acidic organelles, and a swollen structure. Notably, intrinsic resistance was conquered by Cisplatin because of cMYC and IDO-1 downregulation. Additionally, this Cisplatin-CDKI combination induced HLA-ABC and PD-L1 upregulation, which may enhance immunogenicity. Performing functional and molecular analysis on patient-individual HNSCC-models, we identified CDK4-gains as a biomarker for abemaciclib response prediction and describe an approach to conquer intrinsic CDKI resistance.

9 April 2024 in Head & Neck
Verified
Journal Article
Open access
PDF file
ABAnne-Sophie Becker
Anne-Sophie Becker
JMJenny Merkel
Jenny Merkel
IBInci Bozkurt
Inci Bozkurt
DSDaniel Fabian Strüder
Daniel Fabian Strüder
CMClaudia Maletzki
Claudia Maletzki
AZAnnette Helene Zimpfer
Annette Helene Zimpfer
Background: Human papillomavirus (HPV) is an increasing risk factor for cancer. HPV‐associated oropharyngeal squamous cell carcinoma (OPSCC) is associated with a favorable outcome. Blockstaining for p16 is a surrogate marker for HPV+ OPSCC. In oral and laryngeal squamous cell carcinoma (OSCC/LSCC), the relevance of p16 immunohistochemistry, alone or in combination with other cell cycle‐related proteins, to identify HPV‐driven non‐OPSCC is less well understood.Methods: We stained for p16, pRb, cyclin D1, and p53 in 327 HNSCC. In 310 OPSCC, HPV‐status was assessed by HPV DNA PCR. In 119 non‐OPSCC, RNA in situ hybridization was additionally performed. HPV‐status was correlated with staining patterns, p53 and clinical data.Results: The OPSCC showed blockstaining for p16 in 36%, 8% were equivocal. Of these, HPV‐testing was performed in 57%, and 53% were positive for HPV DNA. HPV‐association correlated with absence of pRb and cyclin D1 and favorable outcome. In non‐OPSCC, 18% showed p16‐blockstaining, and 13% showed E6/E7 RNA. Six of seven HPV+ OSCC and 8/8 LSCC lost pRb and cyclin D1. Compared to HPV‐negative counterparts, patients with HPV+ cancers had lower rates of alcohol consumption and keratinizing morphology. HPV‐positive OSCC had a longer overall survival (p < 0.05). HPV subtype 16 was the most common.Conclusions: We conclude that HPV‐positive non‐OPSCC are associated with p16 overexpression and low levels of pRb and cyclin D1. High expression of pRb and cyclin D1 indicates HPV‐negativity.

9 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
HDHayel Derani
Hayel Derani
ABAnne-Sophie Becker
Anne-Sophie Becker
OHOliver Hakenberg
Oliver Hakenberg
AEAndreas Erbersdobler
Andreas Erbersdobler
The “Cellular Dissociation Grade” (CDG) is based on tumor cell budding and cell nest size. Many studies have examined the CDG in squamous cell carcinomas of other organs such as the lungs, oral cavity, pharynx, larynx, cervix and esophagus. In this study, the CDG was examined in 109 cases of invasive penile squamous cell carcinoma that were treated at the University Medicine Rostock between 2014 and 2022. Furthermore, its correlation with the pathologic status of regional lymph nodes (pN) as the main prognostic factor was verified. Finally, cellular dissociation grading was compared with classic WHO grading. The results showed that pN in penile squamous cell carcinoma showed a highly significant association with the CDG and no statistically significant association with WHO grading. These results support the notion that cellular dissociation grading is an important prognostic factor for squamous cell carcinoma.